Literature DB >> 19237882

Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock.

James A Russell1, Keith R Walley, Anthony C Gordon, D James Cooper, Paul C Hébert, Joel Singer, Cheryl L Holmes, Sangeeta Mehta, John T Granton, Michelle M Storms, Deborah J Cook, Jeffrey J Presneill.   

Abstract

OBJECTIVE: Vasopressin and corticosteroids are often added to support cardiovascular dysfunction in patients who have septic shock that is nonresponsive to fluid resuscitation and norepinephrine infusion. However, it is unknown whether vasopressin treatment interacts with corticosteroid treatment.
DESIGN: Post hoc substudy of a multicenter randomized blinded controlled trial of vasopressin vs. norepinephrine in septic shock.
SETTING: Twenty-seven Intensive Care Units in Canada, Australia, and the United States. PATIENTS: : Seven hundred and seventy-nine patients who had septic shock and were ongoing hypotension requiring at least 5 microg/min of norepinephrine infusion for 6 hours.
INTERVENTIONS: Patients were randomized to blinded vasopressin (0.01-0.03 units/min) or norepinephrine (5-15 microg/min) infusion added to open-label vasopressors. Corticosteroids were given according to clinical judgment at any time in the 28-day postrandomization period. MEASUREMENTS: The primary end point was 28-day mortality. We tested for interaction between vasopressin treatment and corticosteroid treatment using logistic regression. Secondary end points were organ dysfunction, use of open-label vasopressors and vasopressin levels. MAIN
RESULTS: There was a statistically significant interaction between vasopressin infusion and corticosteroid treatment (p = 0.008). In patients who had septic shock and were also treated with corticosteroids, vasopressin, compared to norepinephrine, was associated with significantly decreased mortality (35.9% vs. 44.7%, respectively, p = 0.03). In contrast, in patients who did not receive corticosteroids, vasopressin was associated with increased mortality compared with norepinephrine (33.7% vs. 21.3%, respectively, p = 0.06). In patients who received vasopressin infusion, use of corticosteroids significantly increased plasma vasopressin levels by 33% at 6 hours (p = 0.006) to 67% at 24 hours (p = 0.025) compared with patients who did not receive corticosteroids.
CONCLUSIONS: There is a statistically significant interaction between vasopressin and corticosteroids. The combination of low-dose vasopressin and corticosteroids was associated with decreased mortality and organ dysfunction compared with norepinephrine and corticosteroids.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19237882     DOI: 10.1097/CCM.0b013e3181961ace

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  59 in total

Review 1.  [Results of studies in critical care medicine in the year 2009 : update].

Authors:  M Bernhard; G Marx; K Weismüller; C Lichtenstern; K Mayer; F M Brunkhorst; M A Weigand
Journal:  Anaesthesist       Date:  2010-05       Impact factor: 1.041

2.  Part 10: Pediatric basic and advanced life support: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations.

Authors:  Monica E Kleinman; Allan R de Caen; Leon Chameides; Dianne L Atkins; Robert A Berg; Marc D Berg; Farhan Bhanji; Dominique Biarent; Robert Bingham; Ashraf H Coovadia; Mary Fran Hazinski; Robert W Hickey; Vinay M Nadkarni; Amelia G Reis; Antonio Rodriguez-Nunez; James Tibballs; Arno L Zaritsky; David Zideman
Journal:  Circulation       Date:  2010-10-19       Impact factor: 29.690

3.  Impact of low-dose vasopressin on trauma outcome: prospective randomized study.

Authors:  Stephen M Cohn; Janet McCarthy; Ronald M Stewart; Rachelle B Jonas; Daniel L Dent; Joel E Michalek
Journal:  World J Surg       Date:  2011-02       Impact factor: 3.352

4.  Pediatric basic and advanced life support: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations.

Authors:  Monica E Kleinman; Allan R de Caen; Leon Chameides; Dianne L Atkins; Robert A Berg; Marc D Berg; Farhan Bhanji; Dominique Biarent; Robert Bingham; Ashraf H Coovadia; Mary Fran Hazinski; Robert W Hickey; Vinay M Nadkarni; Amelia G Reis; Antonio Rodriguez-Nunez; James Tibballs; Arno L Zaritsky; David Zideman
Journal:  Pediatrics       Date:  2010-10-18       Impact factor: 7.124

Review 5.  Pharmacological optimization of tissue perfusion.

Authors:  N Mongardon; A Dyson; M Singer
Journal:  Br J Anaesth       Date:  2009-05-21       Impact factor: 9.166

6.  Influences of hydrocortisone therapy on arginine vasopressin plasma levels in septic shock.

Authors:  Stefan Jochberger; Martin W Dünser
Journal:  Wien Klin Wochenschr       Date:  2011-04-11       Impact factor: 1.704

7.  Arginine-vasopressin and corticosteroids in septic shock: engaged but not yet married!

Authors:  François Lauzier; Olivier Lesur
Journal:  Intensive Care Med       Date:  2011-07-21       Impact factor: 17.440

Review 8.  Challenges in the management of septic shock: a narrative review.

Authors:  Daniel De Backer; Maurizio Cecconi; Jeffrey Lipman; Flavia Machado; Sheila Nainan Myatra; Marlies Ostermann; Anders Perner; Jean-Louis Teboul; Jean-Louis Vincent; Keith R Walley
Journal:  Intensive Care Med       Date:  2019-02-11       Impact factor: 17.440

9.  Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study.

Authors:  Andrea Morelli; Christian Ertmer; Sebastian Rehberg; Matthias Lange; Alessandra Orecchioni; Valeria Cecchini; Alessandra Bachetoni; Mariadomenica D'Alessandro; Hugo Van Aken; Paolo Pietropaoli; Martin Westphal
Journal:  Crit Care       Date:  2009-08-10       Impact factor: 9.097

Review 10.  Updating the evidence for the role of corticosteroids in severe sepsis and septic shock: a Bayesian meta-analytic perspective.

Authors:  John L Moran; Petra L Graham; Sue Rockliff; Andrew D Bersten
Journal:  Crit Care       Date:  2010-07-13       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.